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The coronavirus disease (COVID-19) outbreak has presented enormous challenges for
healthcare, societal, and economic systems worldwide. There is an urgent global need
for a universal vaccine to cover all SARS-CoV-2 mutant strains to stop the current
COVID-19 pandemic and the threat of an inevitable second wave of coronavirus.
Carbon dioxide is safe and superior antimicrobial, which suggests it should be effective
against coronaviruses and mutants thereof. Depending on the therapeutic regime, CO2
could also ameliorate other COVID-19 symptoms as it has also been reported to have
antioxidant, anti-inflammation, anti-cytokine effects, and to stimulate the human immune
system. Moreover, CO2 has beneficial effects on respiratory physiology, cardiovascular
health, and human nervous systems. This article reviews the rationale of early treatment
by inhaling safe doses of warmed humidified CO2 gas, either alone or as a carrier
gas to deliver other inhaled drugs may help save lives by suppressing SARS-CoV-2
infections and excessive inflammatory responses. We suggest testing this somewhat
counter-intuitive, but low tech and safe intervention for its suitability as a preventive
measure and treatment against COVID-19. Overall, development and evaluation of this
therapy now may provide a safe and economical tool for use not only during the current
pandemic but also for any future outbreaks of respiratory diseases and related conditions.
Keywords: anti-COVID-19, antiviral, anti-cytokine storm, improve COVID-19 symptoms, carrier gas composition,
enhancer antiviral, protect and improve organs function, suppression COVID-19 pandemic
BACKGROUND
The coronavirus disease (COVID-19) outbreak has presented enormous challenges for healthcare
systems worldwide and caused terrible societal and economic impacts. There is also an urgent need
to address health inequality in treating the current COVID-19 pandemic. Even now, scientists are
racing to unravel sometimes conflicting information to understand the source, diagnose, and find
effective treatments for SARS-CoV-2, and to conduct clinical trials of antiviral drugs and vaccines.
Other COVID-19mysteries include the appearance of new symptoms, the relation of silent hypoxia
and sudden deaths, spikes insignificant vessel blockages, and increased risks of clotting (1). The
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therapy for mitigation and suppression of SARS-CoV-2 infection.
virus is now known to be able to target a wide variety of
cells throughout the human body through ACE2 and TMPRSS2
receptors (2) and is believed to have caused a spike in a rare
syndrome: “multi-system inflammatory state requiring intensive
care” in children. Furthermore, the mode of transmission and the
extent of environmental contamination is yet unknown. While
the virus may not technically be airborne, it is definitely borne in
the air as aerosols (3).
One of the most critical unanswered questions is why some
COVID-19 patients develop severe disease, while others do not?
Does the answer hidden in the origin and continuing evolution of
SARS-CoV-2 virus mutation into mild and wild different strains
(4)? Alternatively, does the answer depend on the two phases of
the individual human body immune responses; a protective phase
and a damaging phase due to inflammation-cytokine storms (5)?
Other questions include whether bacterial co-infections such as
bacterial pneumonia and sepsis with antibiotic resistance lead to
increased COVID-19 disease severity and mortality (6) and how
long it will take to create an effective vaccine. Potential SARS-
CoV-2 vaccines have a variety of approaches that depend on viral
life cycles (7), and it is estimated that a vaccine will either arrive
in 1 or 2 years or will never arrive at all. Even if the vaccine trials
are successful, will the new vaccine cover all SARS-CoV-2 mutant
strains, and give full immunity to everyone with no issues when
translation to clinical practice? Can we produce enough, how
much will it cost and who will pay (a particularly important issue
in developing countries)? Can the new vaccine stop the threat of a
second inevitable wave of coronavirus, or other pandemic viruses
emerging to produce a similar situation in the future?
Gas therapy is a highly effective viral inactivation strategy.
Carbon monoxide (CO) gas is very flammable and highly
poisonous and referred to as the “Silent Killer,” because it binds
to the parts of human blood that carry oxygen molecules, so
it chemically blocks the body and organs from getting the
needed oxygen. However, CO gas has also been shown to
have antimicrobial and antiviral activities against infected cells
(8), and two clinical trials (NCT02425579, NCT03799874) have
demonstrated that the administration of low concentrations of
CO is well-tolerated and safe in patients with sepsis-induced
ARDS (9, 10). Similarly, while high concentrations of inhaled
ozone (O3) can damage the lungs, cause chest pain, coughing,
shortness of breath, throat irritation, and worsen chronic
respiratory diseases such as asthma as well as compromise the
ability of the body to fight respiratory infections (11), ozone gas
therapy has been demonstrated to inactivate airborne viruses (12)
and could inactivate the SARS-CoV-2 virus through oxidizing
the sulfhydryl groups in cysteine of the virus-cell (13). There
are also at least four ongoing clinical trials (NCT04290871 -
NCT04306393 - NCT04305457 - NCT04290858) testing the use
of inhaled nitric oxide (NO) gas for patients with COVID-19 (14),
as increasing airway NO levels via gas inhalation or precursor
molecules may improve oxygenation in COVID-19 subjects (15).
As with the other gases, there is another side to NO, which can
be harmful due to the formation of highly toxic and irritating
nitrogen dioxide (NO2) gas and methemoglobinemia (16).
THE HYPOTHESIS AND EVIDENCE
Carbon dioxide (CO2) is a fundamental biological gas and has
been used for medical purposes for over a century due to its
unique properties (Figure 1). Carbon dioxide gas is natural,
biocompatible, chemically stable, and safer than any other
medical gases (NO, O3, or CO). It has been shown to possess
antioxidant and anti-inflammatory properties, to improve blood
oxygenation and enhance oxygen delivery to organs, to protect
and improve lung function, to function as a carrier, or enhancer
gas for drug delivery by rapid and direct open airway inhalation
with easy administration in home, GP, emergency unit, and
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FIGURE 1 | Exceptional physical, biological, and medical properties of warmed humidified CO2 gas.
ICU settings. These unique biological, physical, and medical
properties of CO2 make it a promising anti-COVID-19 therapy
for mitigation and suppression of SARS-CoV-2 infection. Our
hypothesis depends on inhaling precise doses of humidified and
warmed CO2 medical gas, either alone or as a composite carrier
gas with other COVID-19 inhaler medications (bronchodilators,
antivirals, antibiotics, or anti-cytokine agents), to disinfect
the SARS-CoV-2 virus inside the infected human lung, as a
preventative measure to stop coronavirus infection spreading,
and to improve the treatment of mild, moderate, and severe
COVID-19 symptoms. The following benefits and evidence of
using medical carbon dioxide gas support the hypothesis.
Universal Virucidal and Antimicrobial
Activity
Direct inactivation technologies have several limitations against
the current virus. Moist, warm CO2 gas could become a
competitive disinfection technology. Carbon dioxide gas is an
antiviral, antibacterial, and anti-infection agent effective not
only on solid surfaces but also in aqueous solutions and
water treatment settings (17). Heated, un-pressurized carbon
dioxide bubbled through wastewater or aqueousmedia effectively
destroys both waterborne bacteria and viruses (18). Moreover,
supercritical CO2 can in-activate and eliminate coronaviruses
from an animal, human tissues and solid surfaces (19–21).
Supercritical CO2 offers a novel, user-friendly process to sterilize
acellular tissue, such as lung matrices, for use in tissue and organ
engineering (22). CO2 can also enhance the effect of some other
antibacterial agents, further improving the protection imparted
(17). When breathing is impaired, CO2-levels in the human
body drop, which creates a favorable environment for bacterial
growth and a higher risk of infection. Pure CO2 significantly
decreased the growth rate of most viruses and bacteria at body
temperature; this inhibitory effect of CO2 increased exponentially
with time (23). This phenomenon could be attributed to unravels
the secret of structure and function of the Endothelial Surface
Layer (ESL) (24–27). As the venous ESL is probably comprised
of nanobubbles of CO2, generated from tissue metabolism, that
presumably kills the viruses and bacteria exiting to the blood
flow on the way to leaving via the lungs (27). Even though
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the mechanism of inactivation of microorganisms by CO2 is
not yet resolved, there are a number of hypotheses that have
been proposed to explain the unique disinfection action of CO2
gas (28).
CO2 gas is far superior to other similar gases, with much
higher viral inactivation rates at lower temperatures (18–100◦C)
without the need for pressurization (18, 29). CO2 interacts with
water moisture to generate carbonic acid (pH 4.18), a reduced
pH could affect virus and microbial cell inactivation, as lipid
membrane stability is disrupted and permeability to carbon
dioxide increases (30, 31). However, a reduction in the pH of
the medium is not sufficient to account for the antimicrobial
action of CO2, since it shows a specific inhibitory effect which
is greater than that of the other acids used to lower the pH of
media (hydrochloric acid, phosphoric acid, etc.) (32). These acids
do not penetrate the microbial cells as easily as carbon dioxide
(33). Cheng et al. believe that CO2 molecules could enter virus
capsids much more easily than H+ and inactivate the virus (34).
CO2-protein binding could also damage the capsid, inactivating
the virus. Both mechanisms may be active during dense phase
carbon dioxide treatment (DPCD) which has also been shown
to effectively inactivate viruses (31). The warm atmospheric
pressure CO2 gas during DPCD is suggested to have high viral
inactivation effect by penetrating the virus capsid due to the
high density of CO2 with a high interfacial area (α) produced by
the continuous CO2-moist contact surface area (29). Following
this; CO2 can bind inside the capsid proteins through acid/base
interactions (35), producing the high virus inactivation rates
(18). Also, when compared with other gases (Air, O2, N2, and
Argon), CO2 gas has the highest inactivated viruses and bacteria
rates in different NaCl solutions, even at ambient temperatures
and normal atmospheric pressure (18). Recently, Edwards et al.
demonstrate the effectiveness of aerosol administration of nasal
saline comprising calcium and sodium salts diminishes exhaled
particles and acts as a new natural defense against airborne
pathogens in the human airways (36). Moreover, Zare and his
teamwork report that spraying micron-sized water droplets can
act as an effective disinfectant by causing inactivation of over 98%
of the bacteria. They propose that the combined action of reactive
oxygen species present in micron-size water droplets (but not in
bulk water) along with the droplet surface charge is responsible
for the observed bactericidal activity (37). The efficiency of CO2
technology will require adjustment and control of the mechanical
and dynamic behavior of moist CO2 bubbles and properties such
as temperature, flow and density rates, pressure, electrolyte pH,
bubble size and thickness, surfaces area, and duration. All of these
factors contribute to the observed fast microbial death (38).
Safe and Tolerance for Human Clinical
Trials and Treatment
Carbon dioxide (CO2) gas is natural, inexpensive, non-toxic at
low concentrations (5,000 ppm), non-flammable, and readily
available in high purity from a variety of sources. When CO2 gas
dissolves in water, it exists in chemical equilibrium with carbonic
acid (pH = 4.18) which plays an essential role in the bicarbonate
buffer system used to maintain acid-base homeostasis in the
human body. The duration and concentration of carbon dioxide
inhalation may be the key to the effective and protective role of
CO2 gas therapy. A recent study investigated that pre-treatment
by CO2 inhalation for 10min, but not for 60min, could improve
lipopolysaccharide LPS-induced lung injury (39). A pre-clinical
sheep model used perflubron combined with 12% CO2 to re-
open constricted airways treatment for severe acute asthma (40).
As a reference, OSHA has set a CO2 permissible exposure limit
(PEL) of 5,000 ppm over 8 h and 30,000 ppm over 10min. This
compares favorably to CO gas at 50 ppm, NO gas at 25 ppm,
and O3 gas at 0.10 ppm for 8 h. Humans can tolerate up to
10% CO2 before severe adverse effects are encountered (41)
although CO2 tolerance decreases with age (p < 0.0001) (42).
Two clinical trials (NCT02616770 & NCT02334553) showed that
perflubron carried in gas with ascending doses of carbon dioxide
(4, 8, and 12% CO2) administered to healthy subjects was safe
and effective in subjects with mild asthma (43, 44), while other
ongoing clinical trials (NCT03903913) are testing the safety and
tolerability the same formulation in subjects with cystic fibrosis.
Moreover, CO2 concentrations of up to 35% have been applied in
other clinical trial study used “CO2 inhalation challenge model”
through a protected inhalation system to measure the anxiolytic
and panicolytic effects of new test compounds (45, 46).
Suppressing Cytokine Storm
Evidence is accumulating inferring that a subcategory of
patients with acute COVID-19 might experience cytokine storm
syndrome (47). CO2 gas is one of the potential treatment
strategies to dampen an overactive immune system and to
quell a cytokine storm (48, 49). Many researchers have
reported that the presence of CO2 reduces the production
of proinflammatory cytokines such as tumor necrosis factor-
alpha (TNF-α) and interleukins 1 and 6 (IL-1 and IL-
6, respectively), suggesting that the gas temporarily inhibits
macrophage activity via a mechanism that could be associated
with the reduction of the local or systemic pH (50–54).
Carbon dioxide gas can also affect the production of pro-and
anti-inflammatory cytokines in endotoxin-stimulated human
whole blood cultures under hypercapnic, normocapnic, and
hypocapnic conditions (55). In another study, CO2 was shown
to differentially affect the cytokine release of macrophage
subpopulations exclusively via alteration of extracellular pH.
Decreasing the extracellular pH to 6.5 mimicked the effects
of CO2 and a decrease to 5.5 suppressed IL-6 release in cell
lines (53).
Inhaled Carrier Gas Delivery System
CO2 gas has unique safety, chemical stability, biocompatibility,
and properties as well as a higher density than oxygen,
high solubility in tissue and blood and high tolerance in
vascular system (56). CO2 itself is a respiratory stimuli,
enhances mucus clearance, and seems to be a bronchodilator
by general induction of smooth muscle relaxation (57).
Additionally, warmed and humidified CO2 insufflation leads
to an improved body core temperature (BCT) maintenance,
a reduction of the inflammatory and cytokine responses (58,
59) and improved quality of postoperative course, compared
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with standard insufflation (60, 61). Also, it can reduce
intraoperative hypothermia, coagulation dysfunction, early
postoperative cough pain, days to first flatus and solid food
intake, and the length of hospital stays (62). In recent years,
CO2-based technologies have accordingly gained considerable
interest in the pharmaceutical industry. CO2 bubble-generating
carrier systems can be used to locally accumulate a drug at
diseased tissue, reducing side effects on the healthy tissue
and improving their therapeutic effectiveness (63). CO2 may
also be used as an enhancer and carrier gas for delivery
of effective medical agents into a surgical wound (64) or
respiratory diseases such as severe acute asthma and cystic
fibrosis (40, 43, 44).
Clinical Usage and Medical Purposes
Medical carbon dioxide has been used as a pure gas or in
specialized mixtures with other gases in anesthesia, as an
insufflation gas for minimally invasive surgery (65), and in
carboxytherapy (66). It can be used in the expansion of blood
vessels to increase carbon dioxide level after rapid breathing,
and to stimulate breathing after a period of non-breathing (67).
Transdermal carbon dioxide gas therapy is widespread and
uses carbon dioxide gas at high humidity, to increase tissue
blood flow. Tissue oxygenation generates new blood vessels, and
well-oxygenated tissues improve the effectiveness of antibiotic
therapy. This is complemented by the antioxidant effect of CO2
itself, which reduces oxidative stress in open surgery (68), and
improves wound healing (69).
Benefits of Hypercapnic Therapy
Hypercapnic therapy (elevated CO2 levels) has beneficial effects
on the physiology of the respiratory, cardiovascular, and
nervous system. In human critical care, hypercapnic acidosis
(HCA) is frequently acceptable and improves innate immune
function, resistance to infection, and protects and improves lung
functions in patients with advanced lung disease. However, all
these benefits require careful consideration of when and for
how long hypercapnia will be applied. Hypercapnic acidosis,
but not buffered hypercapnia, was reported to reduce the
severity of sepsis-induced lung injury (70). Recent studies
suggest that HCA is protective in the earlier phases of
bacterial pneumonia-induced sepsis, just as HCA is protective
in preclinical models of early and prolonged systemic sepsis
(71). Also, CO2 gas in therapeutic hypercapnia and other forms
of acidosis techniques is an excellent antioxidant and anti-
inflammatory agent (72). Hypercapnic acidosis was associated
with benefits on lung and distant organs in several disease
models, apart from the reduction of ventilation parameters
FIGURE 2 | Suggested protocol for early and daily inhaling CO2 gas (2–4%) itself or composite with other COVID-19 inhaler medications could help in precaution and
protection strategy to coexistence and adaptation with COVID-19 pandemic.
FIGURE 3 | Suggested protocol for early inhaling CO2 gas (4–14%) itself or composite with other COVID-19 inhaler medications could save lives by disinfection and
improve mild and moderate COVID-19 patient treatment.
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such as ventilator-induced lung injury (73), acute respiratory
distress syndrome (ARDS) (74), ischemia-reperfusion injury
(75) and sepsis (76), therapeutic hypercapnia through inspired
carbon dioxide attenuated lung injury, as measured by gas
exchange, reduced cytokine release, lung oedema formation,
and histological lung injury. Hypercapnic acidosis improves
ventilation-perfusion matching that also improves gas exchange
(77), prevents oedema formation (78), clears the alveolar fluid
in pulmonary oedema (79), maintains the integrity of the
blood-brain-barrier and reduces neurologic deficits after trauma
(80). HCA also reduces the oxidative stress that contributes
to pathologic thick mucus gel formation in the lung (81,
82). It is hoped that hypercapnia therapy may offer real
benefits, but well-planned and executed clinical studies will
be required.
Recent COVID-19 Contradictory Studies
The partial pressure of CO2 in the atmosphere varies between
0.03 and 0.06% (83) but forms a high proportion (12.5–13.5%)
with water vapor (1.3%) of the mainstream cigarette smoke (84).
Recent studies have discovered the unusually low prevalence
of current smoking was observed among hospitalized COVID-
19 patients compared to the expected prevalence based on
smoking prevalence in China. This preliminary analysis does
not support the argument that current smoking is a risk factor
for hospitalization for COVID-19, and might even suggest
a protective role (85). Other cross-sectional studies in both
COVID-19 out- and in-patients strongly suggests that daily
smokers have a very much lower probability of developing
symptomatic or severe SARS-CoV-2 infection as compared to
the general population (86, 87). However, on the other hand,
researchers at Baylor College of Medicine, the University of
South Carolina and other institutions have identified tobacco
smoking as a potential risk factor for infection of the COVID-
19 virus, due to increasing the expression of ACE2, the
receptor of SARS-CoV-2, in the lungs (88, 89). These two
contradictory studies support our hypothesis of moist warm
CO2 gas resulted from cigarettes smoking could kill the SARS-
CoV-2 viruses inside the infected lungs of smoker patients,
and that leads to decreasing the infected COVID-19 patient
from the smoker, not the nicotinic or other outcomes of
mainstream cigarette.
TESTING THE HYPOTHESIS (A):
PRECLINICAL STUDY AND INACTIVATION
MECHANISMS
Herein, we recommend preclinical studies to optimize the
relation between disinfection efficacy and toxicity level of
warm humidified CO2 gas while considering other related
parameters to discover the possible mechanism of action of
disinfection by CO2 gas. The temperature inside healthy lungs
is around 37◦C, the pH is between 7.38 and 7.42, and the
relative humidity ranges from 30 to 70%. It is essential to
keep humidity stable as too high humidity provides optimal
conditions for microbial growth, and low humidity and dry air
can dry mucous membranes and make them more susceptible
to infection (90). The SARS-CoV-2 virus is highly stable at
4◦C, but it is very sensitive to heat. It is remarkably stable in
a wide range of pH values (pH 3–10) at room temperature
(22◦C) (91, 92). However, the stability of SARS-CoV-2 under
different environmental conditions of temperature, pressure,
relative humidity, and pH with biological tissue and barriers
require further investigation.
TESTING THE HYPOTHESIS (B): CLINICAL
EVALUATION AND IMPLICATIONS
Whilst the properties and clinical applications of CO2 have been
known for many decades; parameters must be systematically
studied before it can be used in a new clinical setting.
(I) Healthy, Non-symptomatic, Mild, and
Moderate Care Levels
Optimizing the balance between disinfection efficacy and toxicity
of humidified warmed CO2 gas considering other parameters
(temperature, relative humidity, pressure flow and density rates,
electrolyte pH, bubble size and thickness, surfaces area, and
duration) will be key. Different regimes will be needed to
protect healthy and non-symptomatic patients and improve
the condition of those suffering mild and moderate COVD-19
symptoms. Multiple-ascending dose studies in which subjects
with mild to moderate COVID-19 will be enrolled [CO2 max
14%, tolerance decreases with age (p < 0.0001)] (42). The
suggested study could consist of a screening period, a run-in,
dosing and evaluation periods, and a follow-up period. The
dosing and evaluation period of the study could divide into
three connected components. First, a dose-escalation study—
This segment of the treatment period is designed to assess
the safety and tolerability of escalating doses of medical
CO2 gas (2–4%) in a healthy volunteer (Figure 2), and (4,
8, 12, and 14%) in those with mild-moderate COVID-19
symptoms (Figure 3). Second, a daily dosing study - This
segment of the treatment period is designed to assess the
short term (5 days) safety and tolerability of 1–2 times
daily administrations of a fixed dose of medical CO2 gas
in healthy volunteers, and 2–3 times daily administration of
a fixed dose of medical CO2 gas in patients with mild-
moderate COVID-19. Third, a drug delivery study - This
segment of the treatment period is designed to assess the
safety, efficacy, enhancing, and tolerability of humidified
warmed CO2 gas (2–14%) composed with other inhaled
medication such as an antiviral (Remdesivir or IFN-β SNG001),
short-acting bronchodilator, antibiotic, anti-inflammation. The
recommended clinical trial study may well-include placebo-
control, humidified warmed CO2 gas (2–14%), and humidified
warmed CO2 gas (2–14%) composed with other inhaled
medication. Administration can be achieved through using
simple comprised cartridge MDI puffer, portable nebulizer,
or circularize II high-efficiency aerosol drug delivery system
nebulizer in a negative pressure environment. Direct air/oxygen
inhalation for a few minutes can be used to recover patients to
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FIGURE 4 | Suggested supporting treatment protocol depending on time and duration of limited and convenient artificial hypercapnia acidosis (15–25%) that could
help in saving more lives of severe COVID-19 patients.
baseline carbon dioxide levels. A safety monitoring committee
must also review the results from each cohort before deciding
continuation of the study at the next prescribed dose level,
based on consideration of the clinical significance of safety and
tolerability parameters.
(II) Severe Care Level
The damage mechanisms of SARS-CoV-2 are still unclear, with
severe COVID-19 cases are complicated by high mortality rates
due to compromised immune function and a high probability of
antibiotic-resistant secondary infections. Most severe COVID-
19 cases are associated with respiratory failure, with many
already suffering from internal high hypercapnia acidosis (with
humidity levels near 100%) that disrupt not only cardiac
and neurological functions but also immune system function
by suppressing both innate and adaptive immune responses
to viral and bacterial proliferation and infection (54, 93–
96). This dysfunction of the immune system with increasing
SARS-CoV-2 infection can lead to an overreaction of the
immune system (cytokine storm), during which white blood
cells are misdirected to attack and inflame even healthy tissue,
leading to failure of the lungs, heart, liver, intestines, kidneys,
and genitals (Multiple Organ Dysfunction Syndrome, MODS).
This may, in turn, lead to the lungs shutting down (Acute
Respiratory Distress Syndrome, ARDS), which makes absorption
of oxygen difficult. Most deaths due to COVID-19 are due
to respiratory failure. To save the lives of severing COVID-
19 patients, we must first stop the causes of SARS-CoV-2
infection and preventing secondary infections. However, due to
the absence of a specific COVID-19 antiviral treatment, most
severe COVID-19 patients be admitted to the intensive care
unit to fight the symptoms, aiming to lower the mortality rate
through intensive monitoring and supportive organ function
treatments by anti-cytokine medications with artificial blood
purification system machines (97). Herein, we cautiously
suggest that external artificial hypercapnia acidosis (warmed
humidified CO2 15–25%) could be applied to disinfect and
stabilize the lungs of SARS-CoV-2 infected patients and prevent
secondary infections (Figure 4). However, it should only be
considered for severely affected patients if they are already
is connected to life support and artificial blood purification
through mechanical means, and a controlled gas mixture
consisting of 25% CO2 and 75% O2 is delivered through a
protected inhalation system while monitoring a wide range of
physiological parameters, and administering supportive organ
function treatments.
CONCLUSION AND EXPECTING
OUTCOMES
There is an urgent global need for a universal vaccine to cover all
SARS-CoV-2 mutant strains to stop the threat of an inevitable
second wave of coronavirus. Currently, there are hundreds of
clinical trials, but not yet any approved antiviral drugs specific
for the treatment of COVID-19. The physical, biological, and
medical properties of CO2 gas suggest that humified warmed
CO2 gas possesses multiple bioactivities and offer a new concept
to SARS-CoV-2 viral disinfection and COVID-19 treatment.
This inexpensive and broadly applicable therapy could lead to
a massive reduction in the global number of infected, especially
when used as a carrier for delivery of other inhaled drugs and
creates new possibilities for mitigation and suppression of any
COVID-19 second wave, or indeed any new future respiratory
viral pandemic. In the future, more bioactive properties of
CO2 could be identified, and their mechanisms of action
investigated. We believe well-designed clinical trials of CO2 and
its various bioactive properties are warranted to examine its
efficacy against these diseases in human beings. It is hoped that
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this hypothesis will serve as a stimulus for further investigation
into this issue.
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